A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential

A Phase 1, Open-Label, Fixed Sequence, 1-Way Drug-Drug Interaction Study to Investigate the Repeat-Dose Pharmacokinetics of Microgynon, an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel, When Administered Alone and in Combination With Ganfeborole in Healthy Female Participants of Non-Childbearing Potential Aged 18-65 Years Old

This study is designed to assess the pharmacokinetics (PK), safety, and tolerability of Ganfeborole and Microgynon, an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG), when Microgynon is administered alone and in combination with Ganfeborole in healthy female participants of non-childbearing potential.

Study Overview

• Status: Not yet recruiting
• Conditions: Tuberculosis
• Intervention / Treatment: Drug: Ganfeborole; Drug: Microgynon

• Study Type: Interventional
• Enrollment (Estimated): 28
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: US GSK Clinical Trials Call Center; Phone Number: 877-379-3718; Email: GSKClinicalSupportHD@gsk.com
• Study Contact Backup: Name: EU GSK Clinical Trials Call Center; Phone Number: +44 (0) 20 89904466; Email: GSKClinicalSupportHD@gsk.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Participant is 18 to <65 years of age, inclusive, at the time of signing the informed consent.
2. Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ECG).
3. A creatinine clearance of >=75 mL/min.
4. Normal echocardiogram or echocardiogram with normal left ventricular function with at most trace to mild valvular regurgitation is allowed and no valvular stenosis.
5. Body weight >=40.0 kg (99 pounds [lbs]) and body mass index within the range 18.5 up to 30.0 kg/m^2 (inclusive).

6. Participant of Non-childbearing Potential. Participants in the following categories are considered female PONCBP: Postmenopausal female.

   A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

   • A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in individuals not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required, within the Screening period.
   • Females on HRT and whose menopausal status is in doubt must discontinue HRT at least 30 days prior to the start of Treatment Period 1 to allow confirmation of postmenopausal status before study enrollment.
7. Participant is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in the protocol.

8. Additional inclusion criteria:

   • Two FSH tests
   • Negative pregnancy test

Exclusion Criteria:

1. History of known cardiac valve abnormalities
2. Medical history of fatty liver disease
3. Major health conditions (including ovarian, endometrial, cervical, and breast tumours as per the Microgynon label)
4. History of ovarian, endometrial, cervical and breast cancer
5. History of deep vein thrombosis (DVT)
6. Presence of hepatitis B surface antigen at Screening or within 3 months prior to starting study treatment.
7. Positive hepatitis C antibody test result at Screening or within 3 months prior to starting study treatment AND positive on reflex to hepatitis C RNA.
8. Positive HIV-1 and/or -2 antigen/antibody immunoassay at Screening.
9. Alanine aminotransferase (ALT) >1.5×ULN. A single repeat of ALT is allowed within a single screening period to determine eligibility.
10. Bilirubin >1.5×ULN (isolated bilirubin >1.5×ULN is acceptable if bilirubin was fractionated and direct bilirubin <35%).
11. Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
12. Participants with haemoglobin <8.0 g/dL.
13. Any Grade 3 to 4 laboratory abnormality at Screening, inclusive of creatine phosphokinase and lipid abnormalities and ALT, excludes a participant from the study unless the investigator provided a compelling explanation for the laboratory result(s) and has the assent of the sponsor. A single repeat of any laboratory abnormality is allowed within a single screening period to determine eligibility.
14. A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine (indicating active current smoking) at Screening or before the first dose of study treatment.
15. Unable to refrain from the use of prescription (including HRT), or non-prescription drugs including vitamins, herbal and dietary supplements (including St John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study treatment and for the duration of the study. Concomitant medications may be permitted on a case by case basis on the discretion of the medical monitor and the GSK Ganfeborole team.
16. Treatment with any vaccine within 30 days prior to receiving study treatment.
17. Unwillingness to abstain from excessive consumption of any food or drink containing caffeine, grapefruit or grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study treatment(s) until the end of the study.
18. The study will exclude participants who have undergone IVF or other assisted reproductive techniques within 9 months prior to screening or are participating in such programs at the time of screening, or who plan to undergo IVF or other assisted reproductive techniques during the following year.
19. Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives plus 10 days, or twice the duration of the biological effect of the investigational product (whichever is longer).
20. Where participation in the study results in donation of blood or blood products in excess of 500 mL within 56 days.
21. Any significant arrhythmia or ECG finding which would interfere with the safety for the individual participant
22. Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate: <50 or >100 beats per minute; QTcF interval: >450 milliseconds; QTcF interval (Bundle Branch Block): >480 milliseconds.
23. Participants with vitiligo.
24. Participants with hypertension or Type 2 diabetes that cannot be controlled with diet and exercise alone.
25. History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 units. One unit is equivalent to 8 g of alcohol: a half pint (~240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
26. Unable to refrain from tobacco- or nicotine-containing products.
27. History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.

28. Liver safety exclusion criteria:

    • ALT >1.5xULN.
    • Total bilirubin >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN if direct bilirubin is <=1.5xULN.
    • Current or chronic history of liver disease (including fatty liver disease) or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).
    • Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
    • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
    • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.

29. Cardiac safety exclusion criteria:

    • QTcF >450 milliseconds or QTcF >480 milliseconds for patients with bundle branch block.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Microgynon / Ganfeborole + Microgynon Group; Participants receive in Treatment Period 1: Microgynon repeat dosing from Day 1 to Day 10, and in Treatment Period 2: Ganfeborole low dose alone on Day 11, and Ganfeborole high dose once daily (OD) from Day 12 to Day 24 combined with Microgynon repeat dosing (OD) from Day 15 to Day 24.	Drug: Ganfeborole; Participants receive Ganfeborole orally.; Other Names: GSK3036656; Drug: Microgynon; Participants receive Microgynon orally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Area under the plasma concentration-time curve (AUC(0-tau)) over 24 hours of EE and LNG, after repeat dose, alone and in the presence of Ganfeborole on Day 10	On Day 10 at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
AUC(0-tau) over 24 hours of EE and LNG, after repeat dose, alone and in the presence of Ganfeborole on Day 24	On Day 24 at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
Maximum observed concentration (Cmax) of EE and LNG, after repeat dose, alone and in the presence of Ganfeborole on Day 10	On Day 10, at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
Cmax of EE and LNG, after repeat dose, alone and in the presence of Ganfeborole on Day 24	On Day 24, at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC(0-tau) over 24 hours of Ganfeborole in the presence of EE and LNG		On Day 24, at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose
Cmax of Ganfeborole in the presence of EE and LNG		On Days 16, 22 and 23, at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose for each day, and on Days 24 and 25, at 30 minutes pre-dose and 24 hours post-dose for each day
Time of maximum observed concentration (Tmax) of Ganfeborole in the presence of EE and LNG		On Days 16, 22 and 23, at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose for each day, and on Days 24 and 25, at 30 minutes pre-dose and at 24 hours post-dose for each day
Plasma concentration over 24 hours (Ctau) of Ganfeborole in the presence of EE and LNG		On Days 16, 22 and 23, at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose for each day, and on Days 24 and 25, at 30 minutes pre-dose and 24 hours post-dose for each day
Tmax of EE and LNG alone and in the presence of Ganfeborole		On Days 8, 9, 22 and 23, at 30 minutes pre-dose and 24 hours post-dose for each day, and on Days 10, 24 and 25 at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose for each day
Ctau over 24 hours of EE and LNG alone and in the presence of Ganfeborole		On Days 8, 9, 22 and 23, at 30 minutes pre-dose and 24 hours post-dose for each day, and on Days 10, 24 and 25 at 30 minutes pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose for each day
Number of participants with serious adverse events (SAEs)	An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or other situations as per investigator's opinion.	From Day 1 to Day 25
Number of participants with adverse events (AEs) of grade 3 severity or higher	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Grade 3 = severe, Grade 4 = life-threatening, Grade 5= death.	From Day 1 to Day 25
Number of participants with any AEs related to study interventions, overall and by each type of treatment (Microgynon and Ganfeborole)		From Day 1 to Day 25
Number of participants withdrawn from the. treatment/study due to AEs		From Day 1 to Day 25
Number of participants with electrocardiogram (ECG) values of potential clinical importance (PCI)		At Day 11 and Day 25
Number of participants with clinical chemistry laboratory values of PCI		At Days 1, 7, 11, 21 and 25
Number of participants with hematology laboratory values of PCI		At Days 1, 7, 11, 21 and 25
Number of participants with vital signs parameters of systolic blood pressure (SBP), diastolic BP (DBP) and heart rate (HR) of PCI		At Days 1, 7, 11, 21 and 25
Change in sex hormone binding globulin (SHBG) levels following repeat-dose administration of Microgynon		At Screening, Day 10 and Day 24

Collaborators and Investigators

• Sponsor: GlaxoSmithKline
• Collaborators: UNITE4TB consortium

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): November 24, 2026
• Study Completion (Estimated): November 24, 2026

Study Registration Dates

• First Submitted: August 21, 2026
• First Submitted That Met QC Criteria: August 21, 2026
• First Posted (Actual): August 25, 2026

Study Record Updates

• Last Update Posted (Actual): August 25, 2026
• Last Update Submitted That Met QC Criteria: August 21, 2026
• Last Verified: August 1, 2026

More Information

Terms related to this study

• Keywords: Drug-drug interaction (DDI); GSK3036656; Tuberculosis (TB); Non-childbearing potential; Ganfeborole; Microgynon; Ethinylestradiol and Levonorgestrel
• Additional Relevant MeSH Terms: Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Actinomycetales Infections; Mycobacterium Infections; Tuberculosis; GSK656; ethinyl estradiol, levonorgestrel drug combination
• Other Study ID Numbers: 308245; 2026-525790-39 (Other Identifier: EU CT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf
• IPD Sharing Time Frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
• IPD Sharing Access Criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No